Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Healthcare professionals give intradermal injections just below the surface of the skin, creating a small bump called a bleb or wheal. The intradermal injection route has the longest absorption time ...

If you have certain types of arthritis or if you’re having a certain transplant, your doctor might suggest Orencia (abatacept) as a treatment option for you. Orencia is a prescription medication ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...

Receiving monoclonal antibodies to treat COVID-19 used to be a time-consuming process at the UPMC Hamot Infusion Center. The intravenous treatment took about 30 minutes, which came after a nearly hour ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

The Monkeypox vaccine has just been given the green light by the Federal Drug Administration (FDA) to be administered via intradermal injection. This method will allow healthcare professionals to get ...

Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas. This article ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...